Preparation and in vivo evaluation of an intravenous emulsion loaded with an aprepitant-phospholipid complex

References

• Aapro M, Carides A, Rapoport BL, et al. (2015). Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20:1–13.
   PubMed Web of Science ®Google Scholar
• Augustyn B, Stepien P, Poojari C, et al. (2019). Cholesteryl hemisuccinate is not a good replacement for cholesterol in lipid nanodiscs. J Phys Chem B 123:9839–45.
   PubMed Web of Science ®Google Scholar
• Ballatori E, Roila F. (2003). Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46.
   PubMedGoogle Scholar
• Carpentier YA, Dupont IE. (2000). Advances in intravenous lipid emulsions. World J Surg 24:1493–7.
   PubMed Web of Science ®Google Scholar
• Chu T, Zhang Q, Li H, et al. (2012). Development of intravenous lipid emulsion of tanshinone IIA and evaluation of its anti-hepatoma activity in vitro. Int J Pharm 42:76–88.
   Google Scholar
• Driscoll DF. (2006). Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res 23:1959–69.
   PubMed Web of Science ®Google Scholar
• Gnananath K, Nataraj KS, Rao BG. (2017). Phospholipid complex technique for superior bioavailability of phytoconstituents. Adv Pharm Bull 7:35–42.
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deli Rev 46:75–87.
   PubMed Web of Science ®Google Scholar
• Jiao J, Rhodes DG, Burgess DJ. (2002). Multiple emulsion stability: pressure balance and interfacial film strength. J Colloid Interface Sci 250:444–50.
   PubMed Web of Science ®Google Scholar
• Jumaa M, Müller BW. (1998). The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int J Pharm 16:81–9.
   Google Scholar
• Jumaa M, Müller BW. (2001). Development of a novel parenteral formulation for tetrazepam using a lipid emulsion. Drug Dev Ind Pharm 27:1115–21.
   PubMed Web of Science ®Google Scholar
• Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3–16.
   PubMed Web of Science ®Google Scholar
• Kuche K, Bhargavi N, Dora CP, et al. (2019). Drug-phospholipid complex-a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech 20:43.
   PubMed Web of Science ®Google Scholar
• Li Y, Jin W, Yan H, et al. (2013). Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique. Int J Pharm 454:472–7.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhang Y, Yang Z, et al. (2009). Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 366:160–9.
   PubMed Web of Science ®Google Scholar
• Luo LH, Zheng PJ, Nie H, et al. (2016). Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase. Drug Deliv 23:1282–90.
   PubMed Web of Science ®Google Scholar
• Martinez MN, Amidon GL. (2002). A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42:620–43.
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Hamano T, Yokoyama K. (1982). Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann Rheum Dis 41:263–7.
   PubMed Web of Science ®Google Scholar
• Mozuraityte R, Rustad T, Storr I. (2006). Oxidation of cod phospholipids in liposomes: effects of salts, pH and zeta potential. Eur J Lipid Sci Technol 108:944–50.
   Web of Science ®Google Scholar
• Muñoz M, Coveñas R. (2020). The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer? Cancers 12:2682.
   PubMed Web of Science ®Google Scholar
• Navari RM, Mosier MC. (2019). Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. Onco Targets Ther 12:3277–84.
   PubMed Web of Science ®Google Scholar
• Navari RM. (2004). Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 4:715–24.
   PubMed Web of Science ®Google Scholar
• Ni Q, Gao Q, Yu W, et al. (2015). Supercritical carbon dioxide extraction of oils from two torreya grandis varieties seeds and their physicochemical and antioxidant properties. LWT-Food Sci Technol 60:1226–34.
   Web of Science ®Google Scholar
• Ottoboni T, Lauw M, Keller MR, et al. (2018). Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Future Oncol 14:2849–59.
   PubMed Web of Science ®Google Scholar
• Peng C, Liu C, Tang X. (2010). Determination of physicochemical properties and degradation kinetics of triamcinolone acetonide palmitate in vitro. Drug Dev Ind Pharm 36:1469–76.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kondo M, Inagaki A, et al. (2014). A highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer 5:390–7.
   PubMed Web of Science ®Google Scholar
• Tsukiyama I, Hasegawa S, Ikeda Y, et al. (2018). Cost‐effectiveness of aprepitant in japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881–8.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang W, Jiang Y, et al. (2020). Preparation of ursolic acid-phospholipid complex by solvent-assisted grinding method to improve dissolution and oral bioavailability. Pharm Dev Technol 25:68–75.
   PubMed Web of Science ®Google Scholar
• Whateley TL. (2002). Drug delivery and targeting; for pharmacists and pharmaceutical scientists. J Drug Targe 10:637.
   Google Scholar
• Wu Y, Loper A, Landis E, et al. (2004). The Role of biopharmaceutics in the development of a clinical nanoparticle formulation of Mk-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 285:135–146.
   PubMed Web of Science ®Google Scholar
• Yanagikawa A. (1982). Application of lipid particles as a novel carrier for various drugs. J Stage 2:251–7.
   Google Scholar
• Yu YL, Lu Y, Tang X, et al. (2008). Formulation, preparation and evaluation of an intravenous emulsion containing brucea javanica oil and coix seed oil for anti-tumor application. Biol Pharmaceut Bullet 31:673–680.
   PubMed Web of Science ®Google Scholar
• Yue PF, Yuan HL, Li XY, et al. (2010). Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex. Int J Pharm 387:139–146.
   PubMed Web of Science ®Google Scholar
• Zhang T, Li M, Yang R, et al. (2018). Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Int J Pharm 546:61–69.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wei Y, Cao ZJ, et al. (2020). Aprepitant intravenous emulsion based on ion pairing/phospholipid complex for improving physical and chemical stability during thermal sterilization. AAPS PharmSciTech 21:75.
   PubMed Web of Science ®Google Scholar